IL117305A0 - Gene therapy of atherosclerosis by genetically modified monocytes - Google Patents

Gene therapy of atherosclerosis by genetically modified monocytes

Info

Publication number
IL117305A0
IL117305A0 IL11730596A IL11730596A IL117305A0 IL 117305 A0 IL117305 A0 IL 117305A0 IL 11730596 A IL11730596 A IL 11730596A IL 11730596 A IL11730596 A IL 11730596A IL 117305 A0 IL117305 A0 IL 117305A0
Authority
IL
Israel
Prior art keywords
atherosclerosis
gene therapy
genetically modified
modified monocytes
monocytes
Prior art date
Application number
IL11730596A
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL117305A0 publication Critical patent/IL117305A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11730596A 1995-03-02 1996-02-28 Gene therapy of atherosclerosis by genetically modified monocytes IL117305A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9502430A FR2731229B1 (en) 1995-03-02 1995-03-02 GENE THERAPY OF ATHEROSCLEROSIS BY PRODUCTION OF HDL BY MONOCYTAARY LINES

Publications (1)

Publication Number Publication Date
IL117305A0 true IL117305A0 (en) 1996-06-18

Family

ID=9476659

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11730596A IL117305A0 (en) 1995-03-02 1996-02-28 Gene therapy of atherosclerosis by genetically modified monocytes

Country Status (5)

Country Link
AU (1) AU5095796A (en)
FR (1) FR2731229B1 (en)
IL (1) IL117305A0 (en)
WO (1) WO1996027020A1 (en)
ZA (1) ZA961705B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2602946A1 (en) * 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.

Also Published As

Publication number Publication date
WO1996027020A1 (en) 1996-09-06
FR2731229B1 (en) 1997-04-30
ZA961705B (en) 1996-09-10
FR2731229A1 (en) 1996-09-06
AU5095796A (en) 1996-09-18

Similar Documents

Publication Publication Date Title
EP0814846A4 (en) Gene therapy by secretory gland expression
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
GB9514437D0 (en) Inhibition of gene expression
AU6609196A (en) Verification of barcodes
GB9514435D0 (en) Inhibition of gene expression
AU3813395A (en) Method for gene therapy involving suppression of an immune response
IL122976A0 (en) Control of cd44 gene expression for therapeutic use
PL327608A1 (en) Application of xyloglucane endotransglucosidase (xet)
GB9624854D0 (en) Structural part of hf-tight housings
IL117713A0 (en) Gene expression system
HUP9900750A3 (en) Promoters for gene expression
GB9525918D0 (en) Structure of armrest-driven wheelchair
IL123507A (en) Set of structural elements for constructions
IL117305A0 (en) Gene therapy of atherosclerosis by genetically modified monocytes
IL123596A0 (en) Glucocorticoid enhancement of gene expression
GB9506051D0 (en) Gene expression
AU4941096A (en) Self-deleting vectors for gene therapy
AU6171196A (en) Therapeutic uses of ta99
PL323148A1 (en) Esters of crabapenemes
EP0753579A3 (en) Novel promoter and method of gene expression using the same
PL323141A1 (en) Esters of crabapenemes
GB9722498D0 (en) Production of plutonium-containing products
KR0110698Y1 (en) Suspension of autoseat
GB9521711D0 (en) Gene therapy